Regulatory T cells in atherogenesis

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 6, 2012, Pages 503-515

  Sasaki, Naoto ^a   Yamashita, Tomoya ^a   Takeda, Masafumi ^a   Hirata, Ken ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Immune system; Inflammation; Oral immune modulation; Regulatory T cells

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIBODY; CD86 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; OKT 3; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DIABETES MELLITUS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LUPUS VULGARIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES, REGULATORY;

EID: 84863539423     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.10934     Document Type: Review

References (89)

1. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126.
2. Fan J, Watanabe T: Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb, 2003; 10: 63-71.
3. Hansson GK, Libby P: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 2006; 6: 508-519.
4. Galkina E, Ley K: Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol, 2009; 27: 165-197.
5. Shimokama T, Haraoka S, Watanabe T: Participation of T lymphocytes and macrophages in atherogenesis. J Atheroscler Thromb, 1994; 1 Suppl 1: S14-20.
6. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedencellsborg J, Andersson U, Hansson GK: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis, 1999; 145: 33-43.
7. Roselaar SE, Kakkanathu PX, Daugherty A: Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression. Arterioscler Thromb Vasc Biol, 1996; 16: 1013-1018.
8. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A, 1995; 92: 3893-3897.
9. Robertson AK, Hansson GK: T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol, 2006; 26: 2421-2432.
10. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest, 1997; 99: 2752-2761.
11. Whitman SC, Ravisankar P, Elam H, Daugherty A: Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol, 2000; 157: 1819-1824.
12. King VL, Szilvassy SJ, Daugherty A: Interleukin-4 deficiency decreases atherosclerotic lesion formation in a sitespecific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol, 2002; 22: 456-461.
13. Davenport P, Tipping PG: The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol, 2003; 163: 1117-1125.
14. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 2005; 6: 1133-1141.
15. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005; 6: 1123-1132.
16. Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med, 2009; 361: 888-898.
17. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Bockler D, Katus HA, Dengler TJ: Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol, 2009; 183: 8167-8175.
18. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E: Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2010; 121: 1746-1755.
19. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, Guo C, Wang Q, Wang X, Ma C, Zhang Y, Chen W, Zhang L: A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol, 2010; 185: 5820-5827.
20. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G: Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation, 2009; 119: 1424-1432.
21. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z: Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med, 2009; 206: 2067-2077.
22. Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA, Harrison DG: Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol, 2011; 31: 1565-1572.
23. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell, 2008; 133: 775-787.
24. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z: Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med, 2006; 12: 178-180.
25. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH: Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation, 2006; 114: 2047-2055.
26. Mor A, Planer D, Luboshits G, Afek A, Metzger S, Chajek-Shaul T, Keren G, George J: Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol, 2007; 27: 893-900.
27. Sasaki N, Yamashita T, Takeda M, Shinohara M, Nakajima K, Tawa H, Usui T, Hirata K: Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation, 2009; 120: 1996-2005.
28. Mallat Z, Ait-Oufella H, Tedgui A: Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med, 2007; 17: 113-118.
29. Li MO, Flavell RA: TGF-beta: a master of all T cell trades. Cell, 2008; 134: 392-404.
30. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995; 155: 1151-1164.
31. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 2001; 27: 68-73.
32. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 2001; 27: 20-21.
33. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003; 299: 1057-1061.
34. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 2003; 4: 330-336.
35. Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 2003; 4: 337-342.
36. von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol, 2005; 6: 338-344.
37. Shevach EM: Mechanisms of foxp3+ T regulatory cellmediated suppression. Immunity, 2009; 30: 636-645.
38. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol, 2008; 8: 523-532.
39. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+ CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003; 198: 1875-1886.
40. Apostolou I, von Boehmer H: In vivo instruction of suppressor commitment in naive T cells. J Exp Med, 2004; 199: 1401-1408.
41. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science, 1994; 265: 1237-1240.
42. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL: Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A, 1992; 89: 421-425.
43. Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso AS, Wu H, Chen ML, Gandhi R, Miller A, Maron R, Weiner HL: Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med, 2006; 12: 627-635.
44. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL: Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes, 2007; 56: 2103-2109.
45. Wu HY, Quintana FJ, Weiner HL: Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol, 2008; 181: 6038-6050.
46. HY, Center EM, Tsokos GC, Weiner HL: Suppression of murine SLE by oral anti-CD3: inducible CD4+ CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus, 2009; 18: 586-596.
47. Wu HY, Maron R, Tukpah AM, Weiner HL: Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol, 2010; 185: 3401-3407.
48. Oida T, Zhang X, Goto M, Hachimura S, Totsuka M, Kaminogawa S, Weiner HL: CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-betadependent mechanism. J Immunol, 2003; 170: 2516-2522.
49. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, Wu HY, Weiner HL: Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A, 2010; 107: 9765-9770.
50. Xu Q: Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol, 2002; 22: 1547-1559.
51. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol, 2005; 23: 515-548.
52. Sakaguchi S: Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol, 2005; 6: 345-352.
53. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, Hamann A, Wagner H, Huehn J, Sparwasser T: Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med, 2007; 204: 57-63.
54. Kim JM, Rasmussen JP, Rudensky AY: Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol, 2007; 8: 191-197.
55. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN: Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation, 2009; 119: 2904-2912.
56. Harrison DG, Guzik TJ, Lob H, Madhur M, Marvar PJ, Thabet S, Vinh A, Weyand C: Inflammation, Immunity, and Hypertension. Hypertension, 2010;
57. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA: Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev, 2011; 241: 180-205.
58. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S: CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008; 322: 271-275.
59. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S: Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A, 2008; 105: 10113-10118.
60. Gotsman I, Sharpe AH, Lichtman AH: T-cell costimulation and coinhibition in atherosclerosis. Circ Res, 2008; 103: 1220-1231.
61. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, Groux H: Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2003; 108: 1232-1237.
62. van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, van Eden W, van Berkel TJ, Kuiper J: Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation, 2006; 114: 1968-1976.
63. Faria AM, Weiner HL: Oral tolerance. Immunol Rev, 2005; 206: 232-259.
64. van Puijvelde GH, van Es T, van Wanrooij EJ, Habets KL, de Vos P, van der Zee R, van Eden W, van Berkel TJ, Kuiper J: Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol, 2007; 27: 2677-2683.
65. He S, Li M, Ma X, Lin J, Li D: CD4+CD25+Foxp3+ Regulatory T Cells Protect the Proinflammatory Activation of Human Umbilical Vein Endothelial Cells. Arterioscler Thromb Vasc Biol, 2010; 30: 2621-2630.
66. Lin J, Li M, Wang Z, He S, Ma X, Li D: The role of CD4+CD25+ regulatory T cells in macrophage-derived foam-cell formation. J Lipid Res, 2010; 51: 1208-1217.
67. Mor A, Luboshits G, Planer D, Keren G, George J: Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J, 2006; 27: 2530-2537.
68. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloshi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airoldi F, Manfredi AA, Catapano AL, Norata GD: Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 2010; 30: 1832-1841.
69. Tomura M, Honda T, Tanizaki H, Otsuka A, Egawa G, Tokura Y, Waldmann H, Hori S, Cyster JG, Watanabe T, Miyachi Y, Kanagawa O, Kabashima K: Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest, 2010; 120: 883-893.
70. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med, 2003; 9: 1202-1208.
71. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med, 2002; 346: 1692-1698.
72. Chatenoud L, Bluestone JA: CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol, 2007; 7: 622-632.
73. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach F: Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation, 2006; 114: 1977-1984.
74. Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N, Kasis I, Axelrod E, Zolotarov L, Klein A, El Haj M, Gandhi R, Baecher-Allan C, Wu H, Murugaiyan G, Kivisakk P, Farez MF, Quintana FJ, Khoury SJ, Weiner HL: Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol, 2010; 30: 167-177.
75. Weiner HL, da Cunha AP, Quintana F, Wu H: Oral tolerance. Immunol Rev, 2011; 241: 241-259.
76. Huehn J, Hamann A: Homing to suppress: address codes for Treg migration. Trends Immunol, 2005; 26: 632-636.
77. Grainger DJ: Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol, 2004; 24: 399-404.
78. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, Tedgui A: Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res, 2001; 89: 930-934.
79. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, Daemen MJ: Transforming growth factor- beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol, 2002; 22: 975-982.
80. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK: Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest, 2003; 112: 1342-1350.
81. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, Groux H: Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood, 2003; 102: 4052-4058.
82. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science, 2007; 317: 256-260.
83. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y: Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med, 2007; 204: 1775-1785.
84. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F: A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med, 2007; 204: 1757-1764.
85. Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR: TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature, 2008; 453: 236-240.
86. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe, 2008; 4: 337-349.
87. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006; 441: 235-238.
88. Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso A, Wu H, Chen ML, Gandhi R, Miller A, Maron R, Weiner HL: New immunosuppressive approaches: Oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci, 2008; 274: 9-12.
89. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med, 2006; 355: 1018-1028